Alkaline Phosphatase (ALP) - 10 Marks

1. Introduction & Chemistry

• Normal reference range (adults): ~30-120 IU/L (varies by lab and method)
• Serum half-life: ~7 days
• Measurement: Colorimetric method - rate of p-nitrophenol (pNP) formation from hydrolysis of para-nitrophenylphosphate (pNPP) at 410 nm

2. Isoenzymes and Sources

• Bone burns (90% heat inactivation)
• Placenta is heat-stable (0% inactivation) but L-phenylalanine-sensitive
• Intestinal isoenzyme is also L-phenylalanine-sensitive

• Regan isoenzyme: A placental-like ALP isoenzyme found in small proportions of malignant disease (e.g., lung, breast cancers) - acts as a tumor marker

3. Normal Physiologic Variations

• Age: Adolescents have levels 2x adult values due to active bone growth (bone ALP). Levels rise again after age 30 in both sexes
• Sex: Slightly higher in men; perimenopausal women approach male levels; a healthy 65-year-old woman has ALP ~50% higher than a 30-year-old woman
• Pregnancy: Third trimester significantly elevates ALP due to placental isoenzyme
• Postprandial: Eating a fatty meal elevates ALP by ~30% for up to 12 hours in blood group O and B secretors (intestinal isoenzyme released) - hence fasting sample is preferred
• Oral contraceptives and medications: May elevate ALP

4. Conditions Causing ELEVATED ALP

A. Hepatobiliary Causes (Cholestatic pattern)

B. Bone Causes

C. Other Causes

• Malignancy: Regan isoenzyme (ectopic ALP production)
• Renal disease: Renal tubular cells
• Thyroid disorders: Hyperthyroidism (bone effect)
• Benign familial elevation: Intestinal ALP (asymptomatic)

5. Conditions Causing DECREASED ALP

6. Clinical Approach to Elevated ALP

• If GGT/5'-NT is also elevated → hepatobiliary source likely
• If GGT/5'-NT is normal → bone or other non-hepatic source

• Check antimitochondrial antibody (AMA): positive = primary biliary cholangitis
• Liver ultrasound as first imaging step
• If biliary dilation or suspicious lesion: MRCP, ERCP, or EUS
• Consider liver biopsy if etiology unclear

7. Differentiating ALP Isoenzymes in the Lab

8. Clinical Significance - High-Yield Points for PG

1. Cholestatic pattern on LFT: ALP + GGT elevated disproportionately vs. transaminases = obstructive/cholestatic pathology
2. ALP most sensitive for hepatic metastases - more than ALT/AST
3. Wilson disease = low ALP + jaundice + Coombs-negative hemolysis = classic triad (ALP displaced by copper)
4. Paget disease = markedly elevated bone ALP with normal GGT
5. Hypophosphatasia = low ALP + rickets-like picture in children
6. Regan isoenzyme = ectopic ALP in malignancy
7. Isolated ALP elevation in pregnancy = normal (placental origin, third trimester)
8. Bone ALP as a biomarker = used in monitoring treatment response in Paget disease and bone metastases

Summary Table

• Quick Compendium of Clinical Pathology, 5th ed. (p. 4, isoenzyme table and LFTs section)
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease (p. 1394-1395, ALP physiology)
• Goldman-Cecil Medicine, International Ed. (p. 1562, approach to elevated ALP)
• Henry's Clinical Diagnosis and Management by Laboratory Methods (ALP measurement and interferences)

Alkaline Phosphatase (ALP) - Orthopaedic PG Exam Answer (10 Marks)

1. Introduction

• Normal adult serum ALP: ~30-120 IU/L
• Half-life in serum: ~40-48 hours (bone ALP); ~7 days (total ALP)

2. Biochemical Role in Bone - The Orthopaedic Core

• Hydrolyzes inorganic pyrophosphate (PPi) → inorganic phosphate (Pi)
• PPi is a potent inhibitor of hydroxyapatite crystal formation
• By destroying PPi, bone ALP removes this inhibition and promotes hydroxyapatite deposition
• Matrix vesicles budding from osteoblasts are markedly enriched in bone ALP

Key concept: Bone ALP = marker of osteoblast number and activity = marker of BONE FORMATION (not resorption)

3. ALP as a Bone Turnover Marker

4. Orthopaedic Conditions - ALP Levels with Calcium/Phosphorus Profile

5. Disease-Specific Orthopaedic Relevance

A. Paget Disease of Bone (Highest Yield)

• ALP is the single most sensitive and specific marker for diagnosis and monitoring of Paget disease
• ALP reflects the markedly increased osteoblastic bone formation in Paget's
• Extent of elevation correlates with the extent of skeletal involvement (highest when skull is involved)
• In current Paget disease, ALP is typically 2-4x ULN (previously 10x ULN - milder phenotype now seen)
• Bone-specific ALP is more sensitive than total ALP in mild/monostotic disease
• ALP along with urine pyridinium cross-links is used to monitor disease activity
• With bisphosphonate treatment, ALP normalizes - used to monitor treatment response
• Serum and urine calcium are usually normal; may rise with immobilization (e.g., post-fracture)
• Complication: ~1% develop secondary osteosarcoma (higher in polyostotic disease)

B. Rickets and Osteomalacia

• Elevated ALP with low calcium and low phosphorus is classic
• In severe osteomalacia, bone ALP may be markedly raised without increased bone mineralization (due to mineralization defect)
• ALP elevation is due to compensatory osteoblastic hyperactivity
• Familial hypophosphatemic rickets (X-linked dominant, FGF23 mutation): low phosphorus, normal calcium, high ALP - treatment with burosumab (anti-FGF23 monoclonal antibody)

C. Hyperparathyroidism / Brown Tumors

• ALP, calcium, phosphorus, and PTH levels are used to diagnose hyperparathyroidism and differentiate "brown tumors" from giant cell tumors
• In hyperparathyroidism: high Ca, low PO4, elevated ALP, high PTH
• Orthopaedic management = treating actual or impending pathologic fractures

D. Renal Osteodystrophy

• Low calcium, high phosphorus, elevated ALP (due to secondary hyperparathyroidism)
• Bone-specific ALP is useful here because it is not cleared by glomerular filtration (unlike osteocalcin) - preferred marker in renal failure patients

E. Bone Metastases

• ALP is elevated in osteoblastic metastases (e.g., from prostate cancer) reflecting osteoblastic reaction
• ALP is the most sensitive hepatic chemistry analyte for hepatic metastases
• ALP may be normal in purely osteolytic lesions (e.g., multiple myeloma - important distinction)

F. Osteosarcoma

• ALP levels may be elevated in osteosarcoma
• Elevated pre-treatment ALP is associated with worse prognosis
• Post-chemotherapy normalization of ALP indicates good tumor response
• ALP is not a specific tumor marker but is a useful prognostic indicator

G. Fracture Healing

• ALP rises transiently during fracture healing, reflecting osteoblastic callus formation
• Peak at ~2-3 weeks post-fracture; returns to normal once consolidation is complete
• Persistent ALP elevation beyond expected time = non-union or ongoing metabolic bone disease

6. Hypophosphatasia - Low ALP (Critical Orthopaedic Condition)

• Autosomal recessive inborn error of metabolism
• Loss-of-function mutation in ALPL gene (tissue-nonspecific ALP)
• Results in low serum ALP - unable to break down PPi, so PPi accumulates and inhibits mineralization
• Features mimic rickets: bone pain, fractures, deformity, premature tooth loss
• Diagnostic marker: elevated urinary phosphoethanolamine (PEA) - pathognomonic
• Elevated plasma pyridoxal 5'-phosphate (PLP) - another substrate that accumulates
• Treatment: Asfotase alfa (recombinant TNSALP enzyme replacement - now approved)
• Bisphosphonates are contraindicated in hypophosphatasia (they further inhibit mineralization)

7. Monitoring Treatment with ALP

8. Key Exam Points - High-Yield Summary

1. Bone ALP = osteoblast marker = bone formation marker (NOT resorption)
2. Paget disease = highest ALP elevation of all metabolic bone diseases
3. Myeloma = normal ALP despite widespread bone disease (osteolytic, no osteoblastic reaction)
4. Hypophosphatasia = LOW ALP + rickets-like picture - bisphosphonates contraindicated
5. Wilson disease = LOW ALP + jaundice + hemolysis (copper displaces zinc cofactor)
6. Bone-specific ALP preferred in renal failure (not filtered by kidney, unlike osteocalcin)
7. Bisphosphonate treatment response in Paget's is monitored by serial ALP levels
8. Elevated pre-treatment ALP in osteosarcoma = poor prognosis
9. Hungry bone syndrome post-parathyroidectomy: ALP may transiently spike as osteoblasts become hyperactive
10. Physiologic elevation: ALP is 2x adult levels in growing children (bone growth) and in third-trimester pregnancy (placental isoenzyme) - NOT pathological

• Rockwood and Green's Fractures in Adults, 10th ed. (2025) - Bone turnover marker table; metabolic bone disease lab values
• Campbell's Operative Orthopaedics, 15th ed. (2026) - Paget disease management and monitoring
• Miller's Review of Orthopaedics, 9th ed. - Metabolic bone disease table; hypophosphatasia
• Tietz Textbook of Laboratory Medicine, 7th ed. - Bone ALP biochemistry, role in mineralization, Paget disease monitoring
• Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set - Bone turnover markers; Paget disease treatment

• Navy/teal professional formatting with color-coded tables
• 9 sections covering all orthopaedic-relevant ALP content
• The critical metabolic bone disease lab profile table (Ca / PO4 / ALP) with color highlights
• Hypophosphatasia row in red with bisphosphonate contraindication warning
• High-yield 10-point exam summary in a dark navy table with gold numbering
• Header with document title and footer with page numbers on every page
• All 7 textbook references cited at the end